MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy
Cancer Science · 2026-08 · 117 (8) · 2085-2097
DOI: 10.1111/cas.70429 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 26.05.2026. Verfasst von Hiroaki Ikushima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Purine-Nucleoside Phosphorylase, Neoplasms, Synthetic Lethal Mutations. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mochida Memorial Foundation for Medical and Pharmaceutical Research, Princess Takamatsu Cancer Research Fund, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The homozygous deletion of the chromosome 9p21.3 locus, which includes cyclin‐dependent kinase inhibitor 2A/B ( CDKN2A/B ) and methylthioadenosine phosphorylase ( MTAP ) genes, is one of the most common genomic alterations in cancer. MTAP encodes an essential enzyme in the methionine salvage pathway. Historically, deletions at this locus have been characterized primarily by cell cycle dysregulation driven by CDKN2A/B loss. However, recent studies have revealed that the co‐deletion of MTAP exposes profound metabolic vulnerabilities. Loss of the MTAP function increases cellular dependency on protein arginine methyltransferase 5 (PRMT5). Consequently, targeted PRMT5 inhibition effectively induces synthetic lethality specifically in MTAP ‐deleted tumors. Based on this unique mechanism, the development of novel therapeutic agents exploiting this synthetic lethality is actively underway. In this review, we provide a comprehensive overview of the physiological roles of the MTAP‐PRMT5 axis and the mechanistic principles underlying this synthetic lethality in MTAP ‐deficient cells. Furthermore, drawing upon insights from the analysis of real‐world patient data, we discuss the clinical and molecular characteristics of MTAP ‐deleted tumors, review the landscape of ongoing clinical trials, and explore novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Hiroaki Ikushima
Förderung
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science
- Takeda Science Foundation
- Japan Research Foundation for Clinical Pharmacology
Zitieren
APA
Ikushima, H., & Kage, H. (2026). MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy. Cancer Science, 117(8), 2085-2097. https://doi.org/10.1111/cas.70429
Vancouver
Ikushima H, Kage H. MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy. Cancer Science. 2026;117(8):2085-2097. doi:10.1111/cas.70429
BibTeX
@article{Ikushima2026,
author = {Ikushima, Hiroaki and Kage, Hidenori},
title = {MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {8},
pages = {2085--2097},
doi = {10.1111/cas.70429}
}
EUVIMED